Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 138, Issue , 2013, Pages 10-16

  Stanczyk, Frank Z ^a   Azen, Colleen G ^a   Pike, Malcolm C ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androstanediol glucuronide; Androsterone glucuronide; Dihydrotestosterone; Dihydrotestosterone sulfate; Finasteride

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; ANDROSTERONE; FINASTERIDE; GLUCURONIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

ANDROSTANEDIOL GLUCURONIDE; ANDROSTERONE GLUCURONIDE; DIHYDROTESTOSTERONE; DIHYDROTESTOSTERONE SULFATE; FINASTERIDE;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANDROSTANE-3,17-DIOL; ANDROSTENEDIONE; DIHYDROTESTOSTERONE; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84875313783     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.02.015     Document Type: Article

References (27)

1. J.S. Tenover Prostates, pates, and pimples J.F. Strauss III Clinics in Endocrinology and Metabolism 1991 W.B. Saunders Co. Philadelphia 893 909
2. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, J.D. Winkler, and T.M. Penning Discovery of substituted 3-(phenylamino) benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Bioorganic and Medicinal Chemistry Letters 21 2011 1464 1468
3. V. Luu The assessment of steroidogenic pathways that do not require testosterone as an intermediate Hormone Molecular Biology and Clinical Investigation 5 2011 161 165
4. D.W. Russell, and J.D. Wilson Steroid 5α-reductase: two genes/two enzymes Annual Review of Biochemistry 63 1994 25 61
5. A.E. Thigpen, R.I. Silver, J.M. Guileyardo, M.L. Casey, J.D. McConnell, and D.W. Russell Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression Journal of Clinical Investigation 92 1993 903 910 (Pubitemid 23262413)
6. R.S. Rittmaster 5α-Reductase inhibitors Journal of Andrology 18 1997 582 587
7. A.R. Kristal, C. Till, C.M. Tangen, P.J. Goodman, M.L. Neuhouser, F.Z. Stanczyk, L.W. Chu, S.K. Patel, I.M. Thompson, J.K. Reichardt, A. Hoque, E.A. Platz, W.D. Figg, A. Van Bokhoven, S.M. Lippman, and A.W. Hsing Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride Cancer Epidemiology Biomarkers and Prevention 21 2012 1823 1832
8. R.V. Clark, D.J. Hermann, G.R. Cunningham, T.H. Wilson, B.B. Morrill, and S. Hobbs Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteridea dual 5α-reductase inhibitor The Journal of Clinical Endocrinology and Metabolism 89 2004 2179 2184 (Pubitemid 38619850)
9. T.M. Penning, M.E. Burczynski, J.M. Jez, C.F. Hung, H.K. Lin, H. Ma, M. Moore, N. Palackal, and K. Ratnam Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochemical Journal 351 Pt 1 2000 67 77
10. S. Steckelbroeck, Y. Jin, S. Gopishetty, B. Oyesanmi, and T.M. Penning Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action Journal of Biological Chemistry 279 2004 10784 10795 (Pubitemid 38379543)
11. V. Guerini, D. Sau, E. Scaccianoce, P. Rusmini, P. Ciana, A. Maggi, P.G.V. Martini, B.S. Katzenellenbogen, M. Motta, and A. Poletti The androgen derivative 5α-androstane-3β,17β-diol (3β-Adiol) inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype Cancer Research 65 2005 5445 5453 (Pubitemid 40827358)
12. D.R. Bauman, S. Steckelbroeck, M.V. Williams, D.M. Peehl, and T.M. Penning Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α, 17β-diol to 5α-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease Molecular Endocrinology 20 2006 444 458 (Pubitemid 43152517)
13. J.L. Mohler, M.A. Titus, and E.M. Wilson Potential prostate cancer drug target: bioactivation of androstanediol by conversion of dihydrotestosterone Clinical Cancer Research 17 2011 5844 5849
14. F. Labrie, A. Bélanger, P. Bélanger, R. Bérube, C. Martel, L. Cusan, J. Gomez, B. Candas, I. Castiel, V. Chaussade, C. Deloche, and J. Leclaire Androgen glucuronides instead of testosterone, as the new markers of androgenic activity in women Journal of Steroid Biochemistry and Molecular Biology 99 2006 182 188 (Pubitemid 43766081)
15. A.W. Hsing, F.Z. Stanczyk, A. Bélanger, P. Schroeder, L. Chang, R.T. Falk, and T.R. Fears Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry Cancer Epidemiol Biomarkers 16 2007 1004 1008 (Pubitemid 46910104)
16. A. Belanger, G. Pelletier, F. Labrie, O. Barbier, and S. Chouinard Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans Trends in Endocrinology and Metabolism 14 2003 473 479 (Pubitemid 37517349)
17. R.J. Cote, E.C. Skinner, C.E. Salem, S.J. Mertes, F.Z. Stanczyk, B.E. Henderson, M.C. Pike, and R.K. Ross The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels British Journal of Cancer 78 1998 413 418 (Pubitemid 28336432)
18. U. Goebelsmann, G.S. Bernstein, J.A. Gale, O.A. Kletzky, R.M. Nakamura, A.H. Coulson, and J.J. Korelitz Serum gonadotropin testosterone estradiol and estrone levels prior to and following bilateral vasectomy I.H. Lepow, R. Crozier, Vasectomy: Immunologic and Pathophysiologic Effects in Animals and Man 1979 Academic Press New York 165 175
19. U. Goebelsmann, R. Horton, J.H. Mestman, J.J. Arce, Y. Nagata, R.M. Nakamura, I.H. Thorneycroft, and D.R. Mishell Jr. Male pseudohermaphroditism due to testicular 17-hydroxysteroid dehydrogenase deficiency The Journal of Clinical Endocrinology and Metabolism 36 1973 867 879
20. P. Serafini, and R.A. Lobo Increased 5α-reductase activity in idiopathic hirsutism Fertility and Sterility 43 1985 74 78 (Pubitemid 15198278)
21. 19 conjugates Journal of Clinical Endocrinology and Metabolism 75 1992 768 772
22. J.F. Steiner Clinical pharmacokinetics and pharmacodynamics of finasteride Clinical Pharmacokinetics 30 1996 16 27 (Pubitemid 26030418)
23. R.W. Norman, K.E. Oakes, A.S. Wright, and R.S. Rittmaster Androgen metabolism in men receiving finasteride before prostatectomy Journal of Urology 150 1993 1736 1739 (Pubitemid 24346938)
24. G. Carruba Estrogen and prostate cancer: an eclipsed truth in an androgen-dominant scenario Journal of Cellular Biochemistry 102 2007 899 911 (Pubitemid 350036930)
25. R.S. Rittmaster Androgen conjugates: physiology and clinical significance Endocrine Reviews 14 1993 121 132 (Pubitemid 23066536)
26. I. Morimoto, A. Edmiston, D. Hawks, and R. Horton Studies on the origin of androstanediol and androstanediol glucuronide in young and elderly men The Journal of Clinical Endocrinology and Metabolism 52 1981 772 778 (Pubitemid 13235900)
27. S.T. Page, D.W. Lin, E.A. Mostaghel, B.T. Marck, J.L. Wright, J. Wu, J.K. Amory, P.S. Nelson, and A.M. Matsumoto Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial The Journal of Clinical Endocrinology and Metabolism 96 2011 430 437